ArticleResearch square2025
Oligodendrocyte progenitor cell responses to inflammatory demyelination with aging.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oligodendrocyte progenitor cells (OPCs) have the capacity to self-renew, differentiate into mature myelinating cells, and remyelinate the central nervous system in response to demyelination. Normal aging is associated with a reduction in the functional capacity of OPCs and induces distinct transcriptional signatures even in the absence of an autoimmune inflammatory demyelination insult. To determine how aging impacts the OPC response to an acute inflammatory insult comparable to a demyelinating event in multiple sclerosis (MS), we performed adoptive transfer of young myelin-reactive Th17 T cells into young and aged mice. Spinal cord OPC responses were quantified using lineage tracing and myelin sheath thickness was quantified using transmission electron microscopy. In the subacute phase 9-10 days after adoptive transfer, the density of both young and aged OPCs is enriched in spinal cord lesions compared to non-lesion white matter. After adoptive transfer, the density of aged OPCs is significantly higher than naïve/non-adoptive transfer aged spinal cord. Differentiated oligodendrocytes (OLs) are relatively preserved within lesions of aged and young animals despite an overall reduction in OL density after adoptive transfer. While lineage tracing identified newly formed oligodendrocytes after adoptive transfer in both young and aged lesions, less oligodendrocyte differentiation was observed in aged animals. Despite the reduction of OPC differentiation in aged animals, there was no significant difference in the extent of remyelination observed for young and aged lesions. Aged OPCs rise to the challenge in response to a strong auto-immune attack, suggesting that compensatory strategies allow both young and aged OPCs to survive and remyelinate in the inflammatory environment. Identifying pathways that promote resilience of young and aged OPCs in the face of an inflammatory challenge will facilitate the development of remyelinating therapies for the treatment of people with MS across the full spectrum of human aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.